文献速递膀胱癌与上尿路尿路上皮癌

TAR-200在拒绝或无法接受根治性治疗的肌层浸润性膀胱癌患者中的安全性、耐受性和初步疗效:一项1期研究

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
PubMed 文献 · J Urol · 2023-04-07

这项1期研究评估了TAR-200(一种膀胱内吉西他滨缓释给药系统)在35例拒绝或无法接受根治性治疗的肌层浸润性膀胱癌患者中的安全性、耐受性和初步疗效。患者接受连续4个21天周期的TAR-200治疗,3个月时完全缓解率为31.4%,部分缓解率为8.6%,总缓解率为40.0%。中位总生存期为27.3个月,中位缓解持续时间为14个月。

要点

  • TAR-200在老年体弱肌层浸润性膀胱癌患者中总体安全、耐受良好。
  • 3个月时完全缓解率为31.4%(11/35),总缓解率为40.0%(14/35)。
  • 中位总生存期为27.3个月,中位缓解持续时间为14个月。

核心结论

  • TAR-200在治疗选择有限的老年体弱肌层浸润性膀胱癌患者队列中总体安全、耐受良好,并具有有益的初步疗效。

研究设计与样本

  • 1期TAR-200-103研究,纳入35例cT2-cT3bN0M0膀胱尿路上皮癌患者,TAR-200连续4个21天周期(共84天)膀胱内给药。

主要发现

  • 35例入组患者中位年龄84岁,大多数为男性(24/35,68.6%)。
  • 15例患者发生与TAR-200相关的治疗中出现的不良事件,2例患者因治疗中出现的不良事件导致TAR-200取出。
  • 3个月时完全缓解率为31.4%(11/35),部分缓解率为8.6%(3/35),总缓解率为40.0%(14/35;95% CI 23.9-57.9)。
  • 中位总生存期为27.3个月(95% CI 10.1-不可估计),中位缓解持续时间为14个月(95% CI 10.6-22.7)。
  • 12个月无进展率为70.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Half of patients with muscle-invasive bladder cancer worldwide may not receive curative-intent therapy. Elderly or frail patients are most affected by this unmet need. TAR-200 is a novel, intravesical drug delivery system that provides sustained, local release of gemcitabine into the bladder over a 21-day dosing cycle. The phase 1 TAR-200-103 study evaluated the safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who either refused or were unfit for curative-intent therapy. MATERIALS AND METHODS: Eligible patients had cT2-cT3bN0M0 urothelial carcinoma of the bladder. TAR-200 was inserted for 4 consecutive 21-day cycles over 84 days. The primary end points were safety and tolerability at 84 days. Secondary end points included rates of clinical complete response and partial response as determined by cystoscopy, biopsy, and imaging; duration of response; and overall survival. RESULTS: Median age of the 35 enrolled patients was 84 years, and most were male (24/35, 68.6%). Treatment-emergent adverse events related to TAR-200 occurred in 15 patients. Two patients experienced treatment-emergent adverse events leading to removal of TAR-200. At 3 months, complete response and partial response rates were 31.4% (11/35) and 8.6% (3/35), respectively, yielding an overall response rate of 40.0% (14/35; 95% CI 23.9-57.9). Median overall survival and duration of response were 27.3 months (95% CI 10.1-not estimable) and 14 months (95% CI 10.6-22.7), respectively. Progression-free rate at 12 months was 70.5%. CONCLUSIONS: TAR-200 was generally safe, well tolerated, and had beneficial preliminary efficacy in this elderly and frail cohort with limited treatment options.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tyson MD, Morris D, Palou J, et al. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. J Urol. 2023. PMID: 37026631. doi:10.1097/JU.0000000000003195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。